UK TEL: +44 (0) 1234 780020 | USA TEL: +1 888 381 6870
Global Access Diagnostics' (GADx) internal product pipeline is focused on some of the most important areas of human healthcare and agriculture. We understand that rapid and accurate point-of-care diagnostics empowers ordinary people to enjoy technology outside of laboratory, in order to achieve better outcomes, no matter if it’s in health or industry.
Our research team of over 40 scientists have been at the forefront of rapid diagnostic test development since 2003. At present GADx is developing rapid diagnostic tests in 6 distinct fields of specialty.
Chronic respiratory diseases affect nearly 550 million worldwide. Although these conditions are incurable, treatment is available to manage symptoms. Rapid diagnostic tests are crucial in the early detection of an exacerbation, thereby limiting the potential of unfavourable health consequences and improving the patient’s quality of life.
GADx also focuses on crop and animal health, recognizing the role lateral flow test can play in improving livelihoods by better understanding and managing diseases affecting the agricultural sector.
Lateral flow tests are widely seen as vital tools in the fight against infectious disease. Rapid, point-of-cares tests enable health care workers to make quick decisions near the patient. This can be especially important for life threatening diseases like sepsis. It is also critical in lower resource settings, where access to labs is limited. People shouldn't have to wait days to know what is ailing them.
Rapid Diagnostics for epidemics are critical for the surveillance, containment and elimination of epidemics in the absence of a vaccine programme. Since 2018, GADx has increased its focus on epidemics and neglected diseases, with support from the Gates Foundation, the Wellcome Trust, the UK government, and the Foundation for Innovative New Diagnostics (FIND).
By detecting outbreaks early, in settings where laboratory capacity is limited, we can support more precise and responsive public health measures and immunisation campaigns
Neglected diseases affect more than 1.7 billion people, blighting communities across the Global South, and are particularly prevalent in tropical regions that lack basic sanitation. NTDs affect people across all age groups, from impairing children’s development to limiting workplace productivity; therefore, trapping communities into a negative cycle of poverty and poor health.
We are committed to the optimum health for women at every stage of her life and believe this goal is attainable with rapid diagnostic tests. GADx has a long and enviable record with women’s health diagnostics, with our co-founder being one of the inventors of the Clearblue pregnancy test. We are a trusted partner that healthcare professionals and patients can depend on, when it comes to developing women’s health diagnostics.
GADx is currently developing diagnostic tests for bacterial vaginosis (BV), which affects up to 30% of women during reproductive age, and Urinary Tract Infections (UTI) which affects 2-in-5 women during her lifetime.
To meet global food security and reduce carbon footprint, the drive is to focus on Intensification of farming. Concentrating crops and animals in defined space requires innovative sustainable strategies to retain food safety. Early, cost-effective, accurate diagnosis applied at critical points can inform early disease outbreaks and drive the correct control strategy.
Tests must deliver on cost-effectiveness, ease of use at point-of-need with results that are actionable. Lateral flow tests deliver on these and provide a long term respected technology.
Mologic Ltd trading as Global Access Diagnostics. Company registered in England and Wales .Company Registration No. 4784437 | All Rights Reserved